研究还发现，传统听觉相关基因在拥有回声定位能力的哺乳动物海马区调控网络中异常活跃，可能 参与空间定位等功能构建。 此项研究还突破了传统研究主要关注蛋白质编码基因趋同进化的局限，证实非编码调控区域的进化 重复性同样是行为趋同的关键驱动力。 在漫长历史中，至少有蝙蝠、齿鲸、猪尾鼠等5个远缘哺乳动物类群独立形成了回声定位的本领。 尽管这种能力依赖的听觉系统和神经处理机制在不同物种中高度特化，但展现出惊人的功能相似性，是 研究自然选择如何重复塑造复杂性状的理想模型。 研究团队创新性整合染色质可及性测序、转录组测序和透射电镜等技术手段，系统比较中华菊头 蝠、普通长翼蝠等回声定位蝙蝠与大娄山猪尾鼠的海马区基因调控特征。 研究发现，这些物种的海马区存在222个共享开放染色质区域，数量显著高于随机预期。共享区域 在回声定位物种中促进形成更复杂的基因调控网络，与突触可塑性相关通路密切相关。透射电镜观察结 果显示，大娄山猪尾鼠海马区突触密度和线粒体密度显著高于实验室小鼠，与基因调控网络预测的功能 强化结果一致。 原标题：哺乳动物回声定位趋同机制揭示 记者6月9日从中国科学院昆明动物研究所获悉，该所研究员施鹏团队与刘振团队合作，首 ...

编辑丨王多鱼 排版丨水成文 撰文丨王聪 在哺乳动物 （包括人类和小鼠） 中，性别由性染色体决定： XX 为雌性， XY 为雄性。但实际上，染色体 只是蓝图，真正的性别分化需要精确的基因表达程序。 孕妇通常被建议补铁，以防止怀孕期间常见的"缺铁性贫血"，而一项最新的 Nature 研究显示，孕期缺铁的 可能会对胎儿的性别发育产生深远影响—— 孕期小鼠缺铁，竟会导致性染色体为 XY 的小鼠胚胎发育出卵 巢 ！ 2025 年 6 月 4 日， 大阪大学的 立花诚 （ Makoto Tachibana ） 团队在国际顶尖学术期刊 Nature 上发 表了题为： Maternal iron deficiency causes male-tofemale sex reversal in mouse embryos 的研究论 文。 这项研究发现， 怀孕小鼠缺铁， 会导致其腹中小鼠胚胎从雄性向雌性的性别逆转 ——具有 XY 染色体的 雄性小鼠发育出 卵巢 。这一重磅发现揭示了哺乳动物的铁代谢与性别决定之间存在关联。 铁元素 ，特别是二价铁离子 （Fe²⁺） 对于生命至关重要，众所周知，它是负责运输氧气的血红蛋白的核 心。而这 ...

Core Viewpoint - The research conducted by the team led by Academician Cao Xiaofeng from the Chinese Academy of Sciences provides direct molecular evidence supporting the theory of "acquired inheritance" by demonstrating that environmentally induced epigenetic variations can mediate adaptive traits across generations in rice [2][10]. Group 1: Research Findings - The study established a multi-generational cold stress screening system, successfully obtaining rice strains with significantly enhanced cold resistance that exhibit stable inheritance over at least five generations after the removal of cold stress [4][7]. - The research identified a key variation site in the promoter region of the Arabidopsis galactin gene ACT1, where the loss of methylation allows for the expression of ACT1 to no longer be suppressed by low temperatures [5][8]. - The findings revealed a complete regulatory pathway for cold adaptation, where low-temperature stress downregulates the expression of DNA methyltransferase MET1b, leading to the loss of DNA methylation at the ACT1 promoter, which activates ACT1 expression and confers cold resistance to rice [7][10]. Group 2: Implications for Agriculture - The research introduces a new breeding strategy termed "adversity domestication-epigenetic variation identification-precise editing," which offers innovative solutions for agricultural production challenges posed by global climate change [2]. - The study's analysis of DNA methylation in 131 local rice varieties from three major rice-growing regions in China indicates a "south high, north low" gradient in DNA methylation status of ACT1, suggesting that epigenetic variation is a key domestication site for cold adaptation in rice as it migrates northward [8].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 随着年龄的增长，肝脏更容易出现 代谢功能障碍相关脂肪性肝炎 （MASH） 纤维化。破解衰老、肝脏中衰老细胞的出现与 MASH 纤维化之间复杂的相互作用， 对于开发治疗方法至关重要。 2025 年 5 月 19 日， 中国科学院脑科学与智能技术卓越创新中心 蔡时青 团队与 复旦大学公共卫生中心 涂传涛 团队合作，在 Nature 子刊 Nature Aging 上发 表了题为： Targeting the chromatin remodeler BAZ2B mitigates hepatic senescence and MASH fibrosis 的研究论文。 该研究首次揭示，表观遗传调控因子 BAZ2B 在 肝脏衰老 及 代谢功能障碍相关性脂肪肝炎 （MASH） 纤维化中的关键作用，为开发新型治疗策略奠定理论基 础。 在这项新研究中，研究团队揭示了一种表观遗传机制，该机制将肝脏衰老与 MASH 纤维化联系起来。 研究团队发现，在部分肝细胞中染色质重塑因子 BAZ2B 的上调与患者的 MASH 病理有关。 在小鼠模型中，通过基因敲除或肝细胞特异性敲低 Baz2b 可通过 ...

Company Overview - Microchip Biotech is a pioneer in original innovative drugs in China, focusing on providing clinically needed revolutionary mechanism drugs for patients [7][38] - The company has established a complete industrial chain layout from early exploratory discovery to commercialization, offering original innovative drugs globally [38] Financial Performance - For the fiscal year 2024, the company reported a net profit attributable to shareholders of -114.57 million yuan, with the parent company achieving a net profit of -88.42 million yuan [5] - The board decided not to distribute cash dividends or issue bonus shares for the fiscal year 2024, despite having positive undistributed profits [5] Product Pipeline - The company has developed two innovative drugs, with multiple indications approved for sale globally, including in the fields of malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments [7][39] - Key products include: - **Sida Benamide (西达本胺)**: A first-in-class HDAC inhibitor with multiple indications approved in China and Japan, including for peripheral T-cell lymphoma and breast cancer [8][9][39] - **Siglitazone (西格列他钠)**: A first-in-class PPAR agonist approved for type 2 diabetes and recently for combination therapy with metformin [12][13][40] Research and Development - The company employs a team of experienced scientists to drive drug development, focusing on understanding disease mechanisms and optimizing drug design [22] - The R&D pipeline includes several promising candidates targeting various cancers and metabolic diseases, with ongoing clinical trials demonstrating significant efficacy [17][21][40] Industry Context - The biopharmaceutical industry in China is rapidly evolving, with increasing participation in global biotech innovation and a focus on meeting domestic healthcare needs [26][30] - Despite a low-risk appetite in global financing, Chinese companies are becoming significant players in licensing transactions, with a notable increase in outbound licensing activities [29][41] - The market for innovative drugs in China is projected to grow significantly, with a forecasted market size of approximately $197 billion by 2025 [30]

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Luis Santos - H.C. Wainwright Maury Raycroft - Jefferies Nicole Germino - Truist Gena Wang - Barclays Operator Good afternoon, and welcome ...